Systematic Review Finds Cannabinoids Show Promise for IBD Symptoms but Optimal Dose and Delivery Remain Unknown

The majority of selected studies reported reduced clinical complications as measured by Mayo scores, CDAI, Lichtiger Index, and Harvey-Bradshaw Index, along with weight gain and improved patient wellbeing. However, outcomes were highly heterogeneous across study designs, disease activity measures, treatment durations, administration modes, and dosing protocols.

Systematic review following PRISMA guidelines, examining published research from 2012-2022 on cannabinoid use in IBD treatment. Assessed outcomes including clinical activity indices, symptom relief, and general wellbeing.

IBD patients increasingly use cannabis for symptom relief, and 15-40% of IBD patients worldwide report using cannabinoids. This review consolidates the evidence, confirming promising signals while honestly acknowledging that the research is too heterogeneous to guide clinical practice.

The disconnect between patient-reported benefits and the lack of high-quality evidence creates a challenging situation for clinicians. Patients are already using cannabinoids, but physicians cannot confidently recommend specific products, doses, or delivery methods. Standardized randomized controlled trials are urgently needed.

High heterogeneity in study designs, dosing, duration, administration routes, and outcome measures. Many included studies were small or observational. Generalizability limited by inconsistent methodology. Publication bias may favor positive results.